On Tuesday, shares of Sun Pharma rose above 2 percent after the drugmaker announced the launch of FluGuard (Favipiravir 200 mg) at the price of Rs 35 per tablet, for the treatment of mild to moderate cases of COVID-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease.
"With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India's pandemic response," said Kirti Ganorkar, CEO of Sun Pharma's India Business.
The company will work closely with the government and medical community to ensure availability of FluGuard to patients across the country. The stocks of FluGuard® will be available in the market from this week, Sun Pharma said.